Identification of prostate cancer potential therapeutic targets and virtual drug screening through combined Mendelian randomization study, Bayesian colocalization and molecular docking.

ABSTRACT:

Background

Prostate cancer (PCa) faces significant global challenges, including rising incidence and drug resistance. Our research aims to identify novel protein targets for innovative treatments, evaluate potential adverse effects, and find compounds with strong binding affinity.

Methods

We conducted a proteomic Mendelian randomization (MR) study to assess the causal relationship between plasma proteins and PCa risk. Plasma protein data were obtained from the UK Biobank Pharmaceutical Proteomics Project, which includes GWAS data for 2940 plasma proteins. The PCa GWAS data were sourced from the PRACTICAL Consortium me-ta-analysis, encompassing 79,148 patients and 61,106 controls. Plasma proteins with positive MR results were further analyzed for Bayesian colocalization, drug

SUBMITTER: Liang Z 

PROVIDER: S-EPMC12176702 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature